Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: Its implication of posttransplant small-for-size syndrome

Hideaki Uchiyama, Ken Shirabe, Yuki Bekki, Takeo Toshima, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi

Research output: Contribution to journalArticle

Abstract

Background: Wisteria floribunda agglutinin positive human Mac-2 binding protein glycosylation isomer (M2BPGi) has recently developed as a noninvasive serum marker of liver fibrosis. Liver transplant candidates usually have high serum levels of M2BPGi due to advanced cirrhosis. The aim of the present study was to elucidate the kinetics of serum M2BPGi after liver transplantation and the relationships between the level of M2BPGi and graft function. Methods: Fifteen recipients who underwent living donor liver transplantation (LDLT) between June 2015 and January 2016 and whose pretransplant, postoperative day (POD) 1, POD 3, and POD 7 sera were available for measuring M2BPGi were enrolled in this study. Small-for-size syndrome (SFSS) was defined as the presence of cholestasis (total bilirubin >10 mg/dL) on POD 7 and intractable ascites (>1 L/day on POD 14 or >500 ml/day on POD 28) without other specific causes. Results: The median of pretransplant M2BPGi was 9.75 cutoff index (C.O.I.) (range, 3.04-24.49). There was neither any correlation between pretransplant M2BPGi and Model for End-Stage Liver Disease scores (r=0.416, P=0.123) nor Child-Turcotte-Pugh scores (r=-0.221, P=0.428). The levels of M2BPGi dramatically decreased after LDLT (median; 1.48 on POD 1, 1.47 on POD 3, 1.49 on POD 7). However, serum levels of M2BPGi rose again on POD 7 in some recipients and all 4 recipients with serum levels of M2BPGi exceeding 3.00 C.O.I. succumbed to SFSS later. When the cutoff of M2BPGi on POD 7 for predicting SFSS was determined to be 3.06 according to its receiver operating characteristic curve, both the sensitivity and the specificity for predicting later SFSS were 100%. Conclusions: The levels of M2BPGi dramatically decreased after LDLT. A re-rise of M2BPGi predicted later development of SFSS.

Original languageEnglish
Article number41
JournalTranslational Gastroenterology and Hepatology
Volume4
Issue numberMay
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Living Donors
Glycosylation
Liver Transplantation
Carrier Proteins
Serum
Transplants
End Stage Liver Disease
Cholestasis
Bilirubin
Ascites
ROC Curve
Liver Cirrhosis
Fibrosis
Biomarkers

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation : Its implication of posttransplant small-for-size syndrome. / Uchiyama, Hideaki; Shirabe, Ken; Bekki, Yuki; Toshima, Takeo; Harimoto, Norifumi; Ikegami, Toru; Yoshizumi, Tomoharu.

In: Translational Gastroenterology and Hepatology, Vol. 4, No. May, 41, 01.01.2019.

Research output: Contribution to journalArticle

@article{cf3cb695004c446896bcb31f8935c459,
title = "Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: Its implication of posttransplant small-for-size syndrome",
abstract = "Background: Wisteria floribunda agglutinin positive human Mac-2 binding protein glycosylation isomer (M2BPGi) has recently developed as a noninvasive serum marker of liver fibrosis. Liver transplant candidates usually have high serum levels of M2BPGi due to advanced cirrhosis. The aim of the present study was to elucidate the kinetics of serum M2BPGi after liver transplantation and the relationships between the level of M2BPGi and graft function. Methods: Fifteen recipients who underwent living donor liver transplantation (LDLT) between June 2015 and January 2016 and whose pretransplant, postoperative day (POD) 1, POD 3, and POD 7 sera were available for measuring M2BPGi were enrolled in this study. Small-for-size syndrome (SFSS) was defined as the presence of cholestasis (total bilirubin >10 mg/dL) on POD 7 and intractable ascites (>1 L/day on POD 14 or >500 ml/day on POD 28) without other specific causes. Results: The median of pretransplant M2BPGi was 9.75 cutoff index (C.O.I.) (range, 3.04-24.49). There was neither any correlation between pretransplant M2BPGi and Model for End-Stage Liver Disease scores (r=0.416, P=0.123) nor Child-Turcotte-Pugh scores (r=-0.221, P=0.428). The levels of M2BPGi dramatically decreased after LDLT (median; 1.48 on POD 1, 1.47 on POD 3, 1.49 on POD 7). However, serum levels of M2BPGi rose again on POD 7 in some recipients and all 4 recipients with serum levels of M2BPGi exceeding 3.00 C.O.I. succumbed to SFSS later. When the cutoff of M2BPGi on POD 7 for predicting SFSS was determined to be 3.06 according to its receiver operating characteristic curve, both the sensitivity and the specificity for predicting later SFSS were 100{\%}. Conclusions: The levels of M2BPGi dramatically decreased after LDLT. A re-rise of M2BPGi predicted later development of SFSS.",
author = "Hideaki Uchiyama and Ken Shirabe and Yuki Bekki and Takeo Toshima and Norifumi Harimoto and Toru Ikegami and Tomoharu Yoshizumi",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/tgh.2019.05.08",
language = "English",
volume = "4",
journal = "Translational Gastroenterology and Hepatology",
issn = "2224-476X",
publisher = "AME Publishing Company",
number = "May",

}

TY - JOUR

T1 - Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation

T2 - Its implication of posttransplant small-for-size syndrome

AU - Uchiyama, Hideaki

AU - Shirabe, Ken

AU - Bekki, Yuki

AU - Toshima, Takeo

AU - Harimoto, Norifumi

AU - Ikegami, Toru

AU - Yoshizumi, Tomoharu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Wisteria floribunda agglutinin positive human Mac-2 binding protein glycosylation isomer (M2BPGi) has recently developed as a noninvasive serum marker of liver fibrosis. Liver transplant candidates usually have high serum levels of M2BPGi due to advanced cirrhosis. The aim of the present study was to elucidate the kinetics of serum M2BPGi after liver transplantation and the relationships between the level of M2BPGi and graft function. Methods: Fifteen recipients who underwent living donor liver transplantation (LDLT) between June 2015 and January 2016 and whose pretransplant, postoperative day (POD) 1, POD 3, and POD 7 sera were available for measuring M2BPGi were enrolled in this study. Small-for-size syndrome (SFSS) was defined as the presence of cholestasis (total bilirubin >10 mg/dL) on POD 7 and intractable ascites (>1 L/day on POD 14 or >500 ml/day on POD 28) without other specific causes. Results: The median of pretransplant M2BPGi was 9.75 cutoff index (C.O.I.) (range, 3.04-24.49). There was neither any correlation between pretransplant M2BPGi and Model for End-Stage Liver Disease scores (r=0.416, P=0.123) nor Child-Turcotte-Pugh scores (r=-0.221, P=0.428). The levels of M2BPGi dramatically decreased after LDLT (median; 1.48 on POD 1, 1.47 on POD 3, 1.49 on POD 7). However, serum levels of M2BPGi rose again on POD 7 in some recipients and all 4 recipients with serum levels of M2BPGi exceeding 3.00 C.O.I. succumbed to SFSS later. When the cutoff of M2BPGi on POD 7 for predicting SFSS was determined to be 3.06 according to its receiver operating characteristic curve, both the sensitivity and the specificity for predicting later SFSS were 100%. Conclusions: The levels of M2BPGi dramatically decreased after LDLT. A re-rise of M2BPGi predicted later development of SFSS.

AB - Background: Wisteria floribunda agglutinin positive human Mac-2 binding protein glycosylation isomer (M2BPGi) has recently developed as a noninvasive serum marker of liver fibrosis. Liver transplant candidates usually have high serum levels of M2BPGi due to advanced cirrhosis. The aim of the present study was to elucidate the kinetics of serum M2BPGi after liver transplantation and the relationships between the level of M2BPGi and graft function. Methods: Fifteen recipients who underwent living donor liver transplantation (LDLT) between June 2015 and January 2016 and whose pretransplant, postoperative day (POD) 1, POD 3, and POD 7 sera were available for measuring M2BPGi were enrolled in this study. Small-for-size syndrome (SFSS) was defined as the presence of cholestasis (total bilirubin >10 mg/dL) on POD 7 and intractable ascites (>1 L/day on POD 14 or >500 ml/day on POD 28) without other specific causes. Results: The median of pretransplant M2BPGi was 9.75 cutoff index (C.O.I.) (range, 3.04-24.49). There was neither any correlation between pretransplant M2BPGi and Model for End-Stage Liver Disease scores (r=0.416, P=0.123) nor Child-Turcotte-Pugh scores (r=-0.221, P=0.428). The levels of M2BPGi dramatically decreased after LDLT (median; 1.48 on POD 1, 1.47 on POD 3, 1.49 on POD 7). However, serum levels of M2BPGi rose again on POD 7 in some recipients and all 4 recipients with serum levels of M2BPGi exceeding 3.00 C.O.I. succumbed to SFSS later. When the cutoff of M2BPGi on POD 7 for predicting SFSS was determined to be 3.06 according to its receiver operating characteristic curve, both the sensitivity and the specificity for predicting later SFSS were 100%. Conclusions: The levels of M2BPGi dramatically decreased after LDLT. A re-rise of M2BPGi predicted later development of SFSS.

UR - http://www.scopus.com/inward/record.url?scp=85071667294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071667294&partnerID=8YFLogxK

U2 - 10.21037/tgh.2019.05.08

DO - 10.21037/tgh.2019.05.08

M3 - Article

AN - SCOPUS:85071667294

VL - 4

JO - Translational Gastroenterology and Hepatology

JF - Translational Gastroenterology and Hepatology

SN - 2224-476X

IS - May

M1 - 41

ER -